Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cispl…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views Fennec Pharmaceuticals is back in focus after analysts lifted their fair value estimate from US$15.33 to US$17.67 per share, pointing to a higher assessed equity value for the stock. Recent commentary links this change to stronger than expected PEDMARK revenue, broader use across several tumor types, and updated views on operating leverage that are feeding into refreshed models. As you read on, you will see how this evolving narrative could shape the way you track Fennec Pharmaceuticals from... | ||
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ... Fennec Pharmaceuticals Inc (FENC) reports a 78% surge in Q2 2026 net product sales to $17.1 million, achieving record EBITDA and positive EPS amid aggressive commercial expansion. | ||
 Adherex Technologies Q2 Earnings Call Highlights Adherex Technologies (NASDAQ:FENC), operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise. Chief Executive Officer Jeff Hackman said t | ||
 Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares jumped 7. | ||
 Insider Favorites High Growth Companies June 2026 Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 23% over the past year, with earnings projected to grow by 17% annually in the coming years. In this fluctuating environment, identifying growth companies with high insider ownership can be particularly appealing as these firms often demonstrate strong potential and a vested interest from those who know them best. | ||
 Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir | ||
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting Fennec Pharmaceuticals (FRX.TO) said on Friday that new research evaluating Pedmark (sodium thiosulf | MMT Newswires | |
Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ... Fennec Pharmaceuticals Inc (FENC) reports a 73% increase in net product sales and outlines strategic expansions despite rising operating expenses. | ||
 Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary Moby summary of Fennec Pharmaceuticals Inc.'s Q1 2026 earnings call | ||
Adherex Technologies Q1 Earnings Call Highlights Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand. On the company’s first- | ||